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This is an open study to compare the cure rate of cutaneous leishmaniasis
caused by L. major and treated with either paromomycin sulfate or
intralesional injection of meglumine antimoniate. Sixty parasitologi-
cally proven cases with 1-3 lesions were included and divided randomly
into two equal groups; one group received 1 ml of meglumine anti-
monate intradermally every other day for 20 days, the other group
received the ointment containing 15% parmomycin sulfate in urea twice
daily for 20 days. The patients were clinically evaluated at 1 and 6 weeks
after treatment was completed. The results of clinical evaluation at 1
week after treatment completed showed a cure rate of 18 out of 27 (66%)
in the meglumine antimonate injected group and 20 out of 29 (68%) in
the paromomycin sulfate treated group. The chi square test was used to
compare the cure rate between the two groups and showed no significant
difference (p = 0.85).
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L eishmaniases are among the major public healthproblems in many countries of Asia.
Cutaneous leishmaniasis (CL) is the most common form of
leishmaniases. Control strategies have almost all failed
especially in regard of zoonotic forms of the diseases [1].
Presently there is no vaccine available against leishma-
niases [2]. There are two types of CL in Iran; zoonotic CL
(ZCL) caused by L. major and anthroponotic CL (ACL)
caused by L. tropica, and many modalities are used for the
treatment of leishmaniasis [3]. Pentavalent antimonial is
the current standard WHO recommended treatment for
leishmaniasis which requires multiple injections, and has
parenteral disadvantages such as local pain, toxicity and
high cost which have led to the search for alternatives. The
WHO recommendation for ZCL is no treatment except in
patients with multiple lesions, lesions close to a vital organ
and large lesions [1, 4]. Paromomycin ointment has been
shown to be effective in experimental models of murine
leishmaniasis [5-7]. Local paromomycin was considerd for
use in cutaneous leishmaniasis and in a double blind con-
trolled cross-over trial, 20 days topical treatment with 15%
paromomycin in a soft paraffin showed a rate of 77% cure
over 27% cure in the placebo group [8]. A two week course
of 15% paromomycin plus 10% urea treatment in Iran
showed a significantly higher parasitological cure in the
treated group [9]. Later on a 4 week course of the same
formula in Iran showed a significantly higher cure rate than
two weeks (74%) or placebo (59%) [10].
In this open study the efficacy rate of paromomycin sulfate
and intralesional injection of meglumine antimoniate in the
treatment of CL caused by L. major was compared.
Materials and methods
Study design
This study was designed as a randomized, open, compara-
tive clinical trial to evaluate the efficacy of paromomycin
sulfate in comparsion with intralesional injection of meglu-
mine antimonate.
Study population
This study was performed in Mousian, Dehloran; a ZCL
endemic area, located in western Iran.
Ethical considerations
The study was approved by the Army Ethical Committee.
The objective and procedure of the trial were explained in a
simple language to potential candidates and only those
volunteers who signed the informed consent were included
in the study.
Recruitment
This study was performed in a Military Base Clinic from
January to October 2001. Three hundred male CL sus-
pected cases were refered to the clinic. Sixty parasitologi-
cally proven cases of CL, healthy apart from CL, lesions not
in close proximity to a vital organ or joint were included.
Number of lesions 1-3, ulcer size less than 5 cm in diameter,
onset of the lesion less than 3 months, no previous standard
anti-Leishmania treatment, and no history of allergy to the
paromomycin family were recruited. Each patient was in-
terviewed and physically examined before initiation of the
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treatment. A photograph of each patient’s lesion was taken
before and at week 1 after the treatment was completed.
Diagnostic criteria
Cutaneous leishmaniasis was approved by direct smear.
One to three scrapings were taken from the border of the
lesion(s) of each patient, stained with Giemsa stain [11].
Sixty male patients with proven CL were divided randomly
into two equal treatment groups. One group received 1 ml
of meglumine antimoniate intradermally every other day
for 20 days. Each lesion was injected in the upper and
mid-dermis using a 30-gauge needle. Infiltration was thor-
ough and produced a complete blanching at the base of the
lesion [3]. In order to avoid any bias all injections were
performed by the same physician. The second group of
patients was treated with paromomycin sulfate
(0.5 mg/mm2/day) after cleaning the lesion(s) with soap
and water twice a day for 20 days and treated lesions were
left uncovered [9, 10]. The ointments were used under the
observation of medical staff.
Paromomycin sulfate (C23H45N5O14. xH2SO4)
and meglumine antimoniate
Paromomycin ointment used in this trial contained 15%
paromomycin sulfate (MW = 615.65) and 10% urea in 30
gram of white soft paraffin in a collapsible tube. Paromo-
mycin ointment was purchased from Razak Laboratories
Co., Tehran, Iran.
Meglumine antimoniate (Rhone-Poulenc Rorer, Paris,
France) was kindly donated by Ministry of Health and
Medical Education.
Follow up
Follow up and clinical evaluation of the patients were
performed at week 1 and week 6 after the treatment was
completed. The patients were visited once at 6 months after
treatment was completed. Parasitological evaluation was
performed at week 6 only in patients with active lesion(s).
Responses to treatment
Complete cure was defined as complete re-epithelization of
all lesions at one week after cessation of treatment. Patients
with multiple lesions were considered to be cured if all the
lesions were healed.
Partial cure (parasitological cure) was defined when clini-
cal cure had not occurred in any lesion in a patient but no
Leishmania amastigote was found in a direct smear of the
lesion(s), 3 slides were prepared, and stained from each
active ulcer and 1,000 fields were checked (aproximately 3
slides) [11].
Failure of treatment was defined as no clinical cure and no
parasitological cure at one week after cessation of treat-
ment.
Relapse was defined as a reappearance of the lesion after
complete cure.
Statistical analysis
Epi-Info Version 6 was used for data entry and satistical
analysis. Student’s t-test was used to compare the means
and chi-square was used to compare the proportion. All
statistical tests were two tailed. A q-value of < 0.05 was
considered as a significant difference.
Results
Patient characteristics
Sixty parasitologically proven cases were selected and ran-
domly assigned to receive either meglumine antimoniate or
paromomycin sulfate, there was no statistical difference
between the age, weight and lesion characteristics of the
two groups (table 1).
Treatment efficacy
Three of 30 patients in the meglumine antimoniate treat-
ment group and one of the patients in the paromomycin
sulfate group were withdrawn from the study because of
cutaneous reactions like erythematosis, urticaria or lym-
phadenitis with pain, the withdrawn patients were put on
systemic meglumine antimonate and were all cured; 20
mg/kg for 14 days. No systemic toxic reaction attributable
to the drug was observed.
The results as shown in table 2, indicates a complete cure in
18 out of 27 (67%) in the meglumine antimoniate group and
20 out of 29 (69%) in the paromomycin sulfate group which
statistically is not significant (p = 0.85). The partial cure
rate was 7 out of 27 (26%) in the meglumine antimoniate
group and was 3 out of 29 (10%) in the paromomycin
Table 1. Initial characteristics of patients recruited for the
treatment with either paromomycin sulfate ointment or intrale-
sional injection of meglumine antimoniate
Characteristic Paromomycin
sulfate
(N = 30)
Meglumine
antimoniate
(N = 30)
q-
value
Age (year) 20.6 ± 1.2 21.7 ± 2 0.32
Lesion size (mm) 21.7 ± 2.3 25 ± 7 0.21
Lesion duration (days) 37.8 ± 3.5 39 ± 5.1 0.24
No. of lesions per patient 2 2.4 0.10
No. of lesions 60 76 0.035
One lesion 11 3
Two lesions 8 8
Three lesions 11 19
Location of the lesion(s)
Head & neck 15 10 0.36
Upper extremities 25 36
Lower extremities 19 28
Trunk 1 2
Type of lesions
Papular 9 14 0.65
Nodular 5 9
Ulcerative 46 53
Table 2. Results of evaluation at one week after completion of
the treatment
Outcome Paromomycin
sulfate
No. (%)
Meglumine
antimoniate
No. (%)
q-value
Cure 20 (69) 18 (67) 0.85
Partial cure 3 (10) 7 (26) 0.24
Failure 6 (21) 2 (7) 0.65
Total 29 (100) 27 (100)
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sulfate group (not significant). The failure rate was 2 out of
27 (7%) in the meglumine antimoniate group and 6 out of
29 (21%) in the paromomycin sulfate group (not signifi-
cant).
Discussion and conclusion
Leishmaniasis caused by intracellular protozoan of the
genus Leishmania, depends upon the host immune re-
sponse and the Leishmania species, leishmaniasis presents
a wide spectrum of clinical manifestations. Based on the
diversity of epidemiological characteristics, specific to
each species and its environment, vector and reservoir
control are impractical, costly and usually require political
commitment and infrastructures beyond the means of the
countries suffering most from this disease [1, 4, 12]. Anti-
monials are still the first line of treatment for leishmaniasis
[3]. Treatment of CL with antimonials is expensive, needs
multiple injections, is acompanied by side effects and
moreover variations in efficacy and drug resistance are
reported [4, 12, 13]. In Iran only meglumine antimoniate is
available, and usually when a patient has a limited number
of lesions, intralesional injection of meglumine antimoni-
ate is used. Intralesional injection of meglumine antimoni-
ate is as effective as systemic [14] and even leads to a faster
improvement of the lesion [15], but multiple intralesional
injections around the ulcer is very painful and not all
patients tolerate it, intralesional injection also needs special
medical services which are not available in most endemic
areas. In this study intralesional injection of meglumine
antimoniate was compared with paromomycin sulfate.
Paromomycin, like all the aminoglucoside antibiotics, in-
hibits protein biosynthesis in sensitive organisms [16].
Most reports have shown successful topical treatment of
CL with paromomycin containing 12% methylbenzetho-
nium chloride (MBCL) [5-8, 17, 18]. Regarding the fact
that local pain and inflammation are frequently reported
with MBCL, in contrast to the use of paromomycin con-
taining 10% urea [9, 10], in this formulation, urea was
replaced for MBCL. The result of a study in Iran showed
that a 4 week course of treatment is more effective than a
two week course [10].
In summary, paromomycin sulfate has been shown to be
safe and as effective as intralesional injections of meglu-
mine antimonate in the treatment of ZCL caused by L.
major. The rate of self healing varies from case to case and
depends on various factors such as the duration of the
lesion, charecteristics of the lesion etc. Patient memory is
the only way to estimate the lesion(s) duration, there is a
report that showed paromomycin ointment is effective on
ulcerated lesions [19]. WHO recommended not to treat
uncomplicated cases of ZCL or postpone the treatment for
a few weeks until enough immune response is generated
[1]. This strategy is very difficult to implement especially in
new endemic areas in which the residents are not sure of the
self healing nature of the disease. The least beneficial use of
topical paromomycin in endemic areas is to postpone the
use of antimonials for a few weeks, with increasing antimo-
nial resistance in leishmaniasis, the first line anti-
Leishmania drug should be reserved only for complicated
cases of CL. j
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